Italia markets closed
Dow Jones
38.863,79 +64,80 (+0,17%) Nasdaq
17.187,88 +54,76 (+0,32%) Nikkei 225
39.038,16 +354,23 (+0,92%) EUR/USD
1,0765 -0,0038 (-0,36%) Bitcoin EUR
64.795,38 -0,23 (-0,00%) CMC Crypto 200
1.449,05 +2,38 (+0,16%)
SWTX Jun 2024 25.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 10:30AM EDT. Mercato aperto.
| Chiusura precedente | 1,3500 |
| Aperto | 1,3500 |
| Denaro | 0,0000 |
| Domanda | 5,0000 |
| Prezzo d'esercizio | 25,00 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 1,3500 - 1,3500 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1 |
GlobeNewswireSpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
– Presented additional Phase 3 DeFi data at ASCO demonstrating clinically significant reductions in pain and substantial reductions in tumor volume and T2 hyperintensity with nirogacestat treatment – – Completed enrollment of Phase 2 trial evaluating nirogacestat in patients with ovarian granulosa cell tumors – – Highlighted encouraging Phase 1 and 2 clinical data from emerging pipeline programs at AACR and EHA – STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (
© 2024 Yahoo. Tutti i diritti riservati.